JP2024522769A5 - - Google Patents

Info

Publication number
JP2024522769A5
JP2024522769A5 JP2023577713A JP2023577713A JP2024522769A5 JP 2024522769 A5 JP2024522769 A5 JP 2024522769A5 JP 2023577713 A JP2023577713 A JP 2023577713A JP 2023577713 A JP2023577713 A JP 2023577713A JP 2024522769 A5 JP2024522769 A5 JP 2024522769A5
Authority
JP
Japan
Prior art keywords
weeks
pharmaceutical composition
composition according
iptacopan
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522769A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/055639 external-priority patent/WO2022264101A1/en
Publication of JP2024522769A publication Critical patent/JP2024522769A/ja
Publication of JP2024522769A5 publication Critical patent/JP2024522769A5/ja
Pending legal-status Critical Current

Links

JP2023577713A 2021-06-18 2022-06-17 自己免疫性血液学的疾患を治療する方法 Pending JP2024522769A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163212465P 2021-06-18 2021-06-18
US63/212,465 2021-06-18
PCT/IB2022/055639 WO2022264101A1 (en) 2021-06-18 2022-06-17 Method of treating an autoimmune hematological disorder

Publications (2)

Publication Number Publication Date
JP2024522769A JP2024522769A (ja) 2024-06-21
JP2024522769A5 true JP2024522769A5 (cg-RX-API-DMAC10.html) 2025-06-04

Family

ID=82595001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577713A Pending JP2024522769A (ja) 2021-06-18 2022-06-17 自己免疫性血液学的疾患を治療する方法

Country Status (5)

Country Link
US (1) US20240277689A1 (cg-RX-API-DMAC10.html)
EP (1) EP4355329A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024522769A (cg-RX-API-DMAC10.html)
CN (1) CN117500500A (cg-RX-API-DMAC10.html)
WO (1) WO2022264101A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240109861A1 (en) * 2020-12-30 2024-04-04 Medshine Discovery Inc. Series of piperidine-substituted benzoic acid compounds, and use thereof
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
AU2024417894A1 (en) * 2024-01-10 2026-07-30 Hebei Yiling Medicine Research Institute Co. Ltd. Piperidinyl indole derivative, preparation method therefor and use thereof
WO2026093943A1 (en) 2024-10-31 2026-05-07 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN120168469A (zh) 2020-05-18 2025-06-20 诺华股份有限公司 Lnp023的结晶形式

Similar Documents

Publication Publication Date Title
JP2829545B2 (ja) 2’3’―ジデオキシイノシンによるヒトのレトロウィルス感染症の治療
Chapel et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes
JP2024174927A5 (cg-RX-API-DMAC10.html)
Shahar Current therapeutic options in severe Guillain-Barre syndrome
Engqvist et al. Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study
Allan et al. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy
Robak et al. Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura
Tahhan et al. Novel monoclonal antibody therapy in a patient with treatment-refractory warm autoimmune hemolytic anemia
JP2021517144A (ja) Cd47遮断療法およびcd38抗体の組み合わせ
Pirofsky et al. Intravenous immune globulins: a review of their uses in selected immunodeficiency and autoimmune diseases
JP2021152002A5 (cg-RX-API-DMAC10.html)
JP2008526848A (ja) 黄色ブドウ球菌感染を治療する方法
AU2016259320A1 (en) Pharmaceutical compositions
JP2021522241A5 (cg-RX-API-DMAC10.html)
RU2505312C2 (ru) Комплексное лекарственное средство для лечения гриппа различных типов
JP2023531722A5 (cg-RX-API-DMAC10.html)
Kim High-dose intravenous immune globulin impairs antibacterial activity of antibiotics
Aleem et al. Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations (Archived)
US20110301102A1 (en) Compositions and methods for treating myelodysplastic syndrome
US5656628A (en) Use of L-acetylcarnitine for the treatment of AIDS
WO2018091679A1 (en) Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
RU2500422C2 (ru) Комплексное лекарственное средство для лечения вирусных инфекций и способ лечения вирусных инфекций
Hill et al. Intravenous immune globulin use in newborns
JP2023534576A5 (cg-RX-API-DMAC10.html)
RU2473364C2 (ru) Способ лечения клещевого энцефалита